Vitamin D in Fatty Liver Disease

• Status: Completed
• Trial end date: 2019-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the influence of vitamin D in reducing laboratory, elastographic (Fibroscan) and metabolic components of NAFLD. Half of the patients will receive vitamin D (Plivit D3) while the other half will receive placebo

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Rijeka
• Collaborators: Pliva Hrvatska d.o.o.; University of Rijeka
• Treatments: Cholecalciferol; Dihydroxycholecalciferols; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

• signed informed consent

• possibility to follow instruction and the protocol

Exclusion Criteria:

• chronic B or C hepatitis

• usage of hepatotoxic drugs in the period of 6 months before inclusion

• chronic kidney insufficiency (grade 4 and 5), hemodialysis

• any other chronic liver disease

• opioid dependancy

• any malignancy

• HIV seropositivity

• alcohol abuse

• pregnancy

• inability to follow the protocol